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Lytic Resistance of Fibrin Containing Red Blood Cells
Nikolett Wohner, Pe´ter So´tonyi, Raymund Machovich, La´szlo´ Szabo´, Kiril Tenekedjiev,
Marta M.C.G. Silva, Colin Longstaff, Krasimir Kolev
Objective—Arterial thrombi contain variable amounts of red blood cells (RBCs), which interact with fibrinogen through
an eptifibatide-sensitive receptor and modify the structure of fibrin. In this study, we evaluated the modulator role of
RBCs in the lytic susceptibility of fibrin.
Methods and Results—If fibrin is formed at increasing RBC counts, scanning electron microscopy evidenced a decrease
in fiber diameter from 150 to 96 nm at 40% (v/v) RBCs, an effect susceptible to eptifibatide inhibition (restoring 140
nm diameter). RBCs prolonged the lysis time in a homogeneous-phase fibrinolytic assay with tissue plasminogen
activator (tPA) by up to 22.71.6%, but not in the presence of eptifibatide. Confocal laser microscopy using green
fluorescent protein–labeled tPA and orange fluorescent fibrin showed that 20% to 40% (v/v) RBCs significantly slowed
down the dissolution of the clots. The fluorescent tPA variant did not accumulate on the surface of fibrin containing
RBCs at any cell count above 10%. The presence of RBCs in the clot suppressed the tPA-induced plasminogen
activation, resulting in 45% less plasmin generated after 30 minutes of activation at 40% (v/v) RBCs.
Conclusion—RBCs confer lytic resistance to fibrin resulting from modified fibrin structure and impaired plasminogen
activation through a mechanism that involves eptifibatide-sensitive fibrinogen-RBC interactions. (Arterioscler Thromb
Vasc Biol. 2011;31:2306-2313.)
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A reverse correlation between bleeding time and red bloodcell (RBC) count was observed more than a century ago.1
When anemic and thrombocytopenic patients were treated with
transfusion, the correction of the bleeding time correlated with
the corrected hematocrit despite the fall in the platelet count to
pretransfusion levels. Later studies2 confirmed that the pro-
longed bleeding time of severely anemic patients can be cor-
rected with washed RBC transfusion (thus excluding the effect
of plasma factors) at essentially unchanged platelet counts. The
mechanism of RBC contribution to hemostatic function is still
open to question, notwithstanding their known role in the
maintenance of blood viscosity, the chemical signaling of
platelet activation, and the provision of phospholipid support for
the activation of coagulation factors (reviewed by Wohner3).
The solid matrix of hemostatic and pathological blood clots is
composed of fibrin and variable cellular elements, but the
incorporation of RBCs appears to be mediated through a less
specific entrapment than that of platelets.4 Based on binding
data, approximately 2% of fibrinogen, the plasma precursor of
fibrin monomers, is estimated to circulate in vivo in association
with erythrocytes.5 This interaction is not simply a nonspecific
protein adhesion to the cell membrane, but it involves an
erythrocyte receptor6 and a specific domain around residues 207
to 303 of fibrinogen A-chains.7 Recently, the RBC receptor for
fibrinogen has been identified as an integrin related to the
platelet IIb3 receptor with similar eptifibatide sensitivity and
impaired function in Glanzmann thrombasthenia.8 When fibrin-
ogen is converted to fibrin, the presence of RBCs modifies the
structural and viscoelastic characteristics of plasma clots.9,10
Because fibrin structure profoundly affects the subsequent re-
moval of blood clots from the vasculature by tissue plasminogen
activator (tPA)–dependent proteolysis as a basic fibrinolytic
mechanism (reviewed recently by Weisel and Litvinov11 and
Lord12), the presence of RBCs may change the lytic susceptibil-
ity of thrombi, but no direct evidence for such modulation of
fibrin dissolution is currently available. The present study was
undertaken in an attempt to characterize the impact of RBCs on
2 distinct stages of the fibrinolytic process, plasminogen activa-
tion by tPA and fibrin degradation by the generated plasmin, and
correlate it to the observed structural changes caused by the
incorporation of RBCs in pure fibrin clots.
Methods
Isolation and Labeling of RBCs
RBCs were isolated from citrated whole blood collected from
healthy volunteers with venipuncture. Within 1 hour after collection,
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platelet-rich plasma was removed following centrifugation at 150 g
for 10 minutes, and the cell pellet was further centrifuged at 2000 g
for 10 minutes to sediment the RBCs. The RBC pellet was washed
3 times with 10 volumes of 1.5 mmol/L KH2PO4, 8.1 mmol/L
Na2HPO4 buffer, pH 7.4, containing 137 mmol/L NaCl, 2.7 mmol/L
KCl, and 5 mmol/L glucose (PBS) by resuspension and centrifuga-
tion at 1200 g for 5 minutes. RBCs were counted using an Abacus
Junior B hematology analyzer (Diatron GmbH, Vienna, Austria), and
the hematocrit of the RBC suspension was adjusted to 0.8 with PBS.
RBCs were stored for up to 2 hours at room temperature before use.
For the measurements using confocal laser microscopy, washed
RBCs were labeled with Vybrant DiD cell-labeling solution (Invit-
rogen Life Technologies, Budapest, Hungary) by mixing 5 mL of
RBC suspension diluted to a hematocrit of 0.016 in PBS with 25 L
of Vybrant DiD solution for 30 minutes followed by 3 wash cycles
(resuspension/centrifugation at 1200 g for 5 minutes) with PBS. On
the basis of the cell count, the hematocrit of the Vybrant-labeled
RBCs in the final pellet was adjusted to 0.8.
Ball Sedimentation Assay of Fibrin Dissolution
The assay was designed as an alternative to the reference method
from the European Pharmacopoeia for determination of tPA po-
tency,13 adapted for the high opacity of clots containing RBCs. Two
experimental setups were used, in both of which the total amount of
fibrin in the clot was constant, but in Model 1 this was achieved with
increasing extracellular concentrations of fibrinogen (from 7.4 to
12.4 mol/L human fibrinogen, plasminogen depleted, Calbiochem,
La Jolla, CA) compensating for the rising RBC occupancy (from 0 to
40% [v/v]) in a total volume of 2 mL, whereas in Model 2, the
extracellular concentration of fibrinogen was constant (7.4 mol/L)
in a clot volume increasing from 0.8 mL in the absence of RBCs up
to 1.35 mL at 40% (v/v) RBCs. The RBC-fibrinogen mixtures
were supplemented with varying amounts of plasminogen isolated
from human plasma,14 CaCl2, and in certain cases eptifibatide
(GlaxoSmithKline Kft, Budapest, Hungary), so that the final extra-
cellular concentrations in the assay clots were always 0.1 mol/L
plasminogen, 1 mmol/L CaCl2, and 20 mol/L eptifibatide. For all
assays, thrombin of low specific activity (Serva, Heidelberg, Ger-
many) was further purified by ion-exchange chromatography on
sulfopropyl-Sephadex, yielding a preparation with a specific activity
of 2100 IU/mg,15 and 1 IU/mL was considered equivalent to
approximately 10.7 nmol/L by active site titration.16 Clotting and
fibrinolysis were initiated simultaneously in transparent reaction
tubes with a diameter of 0.8 cm by mixing RBC-fibrinogen suspen-
sions with PBS containing thrombin and tPA (Boehringer Ingelheim,
Ingelheim, Germany) at concentrations needed to reach final extra-
cellular values of 85 and 1 nmol/L, respectively. After 15 seconds, a
steel ball with a diameter of 2 mm and a weight of 0.13 g was placed
on the surface of the clot, and the time elapsed until the ball reached
the bottom of the tube (lysis time) was measured as an indicator of
the collapse of identical quantities of fibrin.
Plasminogen Activation Assays
For the plasminogen activation assay on the surface of the clot, RBC
suspensions in fibrinogen were prepared as described above for the
fibrinolytic assay (only plasminogen was applied at a different
concentration, so that the final extracellular value in the clots was
always 0.5 mol/L). The RBC-fibrinogen mixtures were clotted with
16 nmol/L thrombin in a total volume of 75 L in 96-well
microplates for 30 minutes. Thereafter, 150 L of 15 nmol/L tPA
was added to the surface of the clots, and after 30 minutes the fluid
phase was removed in ice-cold tubes and centrifuged at 2000 g for
10 minutes at 4°C to remove cell debris. The plasmin activity in
the supernatant was determined by mixing 100 L of supernatant
and 100 L of 0.2 mmol/L Spectrozyme-PL (H-D-norleucyl-
hexahydrotyrosyl-lysine-p-nitroanilide, American Diagnostica,
Pfungstadt, Germany) and measuring absorbance at 405 nm (activity
was expressed in A405/min). To evaluate the effect of eptifibatide
on plasminogen activation in the absence of fibrin, a 2-stage
activation assay was used, as previously described.17 Briefly,
3 mol/L plasminogen containing no eptifibatide or 20 mol/L
eptifibatide was mixed with 70 nmol/L tPA, samples were taken at
intervals, and the amidolytic activity of the generated plasmin was
measured using 0.1 mmol/L Spectrozyme-PL.
Expression of Fluorescent Chimeric tPA
Variant (tPA-GFP)
Recombinant human tPA-jellyfish green fluorescent protein (GFP)
was constructed and expressed using the Bac-to-Bac baculovirus
expression system as a tPA-C-terminal fusion with enhanced GFP
isolated from the pEGFP plasmid (Clontech, Mountain View, CA),
as described previously.18,19
Confocal Microscopic Imaging in the Course
of Fibrinolysis
RBC suspensions in fibrinogen were prepared as described for the
plasminogen activation assay using Vybrant-labeled RBCs and
replacing 1% of the fibrinogen with Alexa Fluor 546–conjugated
fibrinogen (Invitrogen Life Technologies, Budapest, Hungary). Fi-
brinogen was clotted with 16 nmol/L thrombin for 30 minutes in
0.5-mm-high chambers constructed from glass slides. Thereafter, 60
nmol/L tPA-GFP was added to the edge of the clot, and the
fluorescence (excitation wavelength 488 nm, emission wavelength
525 nm for tPA-GFP detection; excitation wavelength 543 nm,
emission wavelength 575 nm for Alexa Fluor 546–fibrinogen
detection; excitation wavelength 633 nm, emission wavelength 650
nm for Vybrant-labeled RBC detection) was monitored with Confo-
cal Laser Scanning System LSM510 (Carl Zeiss GmbH, Jena,
Germany) taking sequential images of the fluid-fibrin interface at a
distance of approximately 50 m from the glass surface with
identical exposures and laser intensities using a Plan-Neofluar
20/0.5 objective.
Scanning Electron Microscope Imaging of
Thrombi and Fibrin
The RBC-fibrinogen mixtures were clotted with 16 nmol/L thrombin
in a total volume of 100 L, and after 30 minutes clots were placed
into 10 mL of 100 mmol/L Na-cacodylate, pH 7.2, buffer for 24
hours at 4°C. Following repeated washes with the same buffer,
samples were fixed in 1% (v/v) glutaraldehyde for 16 hours. The
fixed samples were dehydrated in a series of ethanol dilutions (20 to
96% [v/v]), a 1:1 mixture of 96% (v/v) ethanol/acetone, and pure
acetone, followed by critical point drying with CO2 in a E3000
Critical Point Drying Apparatus (Quorum Technologies, Newhaven,
United Kingdom). The specimens were mounted on adhesive carbon
discs and sputter coated with gold using a SC7620 Sputter Coater
(Quorum Technologies), and images were taken with an EVO40
scanning electron microscope (Carl Zeiss GmbH).
Morphometric Analysis of Fibrin Structure and
Statistical Procedures
The scanning electron microscope images of thrombi and fibrin were
analyzed to determine the diameter of the fibrin fibers using
self-designed scripts running under the Image Processing Toolbox,
version 7.0, of Matlab 7.10.0.499 (R2010a) (Mathworks, Natick,
MA). For the diameter measurements, a grid was drawn over the
image with 10 to 15 equally spaced horizontal lines, and all fibers
crossed by them were included in the analysis. The diameters were
measured by manually placing the pointer of the Distance tool over
the end points of transverse cross-sections of 300 fibers from each
image (always perpendicularly to the longitudinal axis of the fibers).
The distribution of the data on fiber diameter was analyzed using an
algorithm described previously for identification of a theoretical
distribution that gives the best global fit to several empirical data
sets.20,21 The best-fitted distributions for different samples were
compared using the Kuiper test, and probability values were calcu-
lated with Monte Carlo simulation procedures. When a statistically
significant difference between 2 distributions was established,20 the
numeric characteristics of the central tendency and variance were
considered to be statistically significant. The statistical hypothesis
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testing for differences in other experimental measurements in this
report was performed with the Kolmogorov-Smirnov test (Statistical
Toolbox 7.3 of Matlab).
Results
Thrombi formed in vivo under similar rheological conditions
in large arteries showed remarkable differences in their RBC
content (Supplemental Figure I, available online at http://
atvb.ahajournals.org). Even within a single thrombus, regions
of high and low RBC count could be identified indicating the
prevalence of local factors (blood vessel geometry, flow
pattern) as determinants of thrombus composition. Thus, a
correct understanding of the impact of RBCs on the lytic
susceptibility of such compartmental architecture should be
based on data modeling the structure and lysis of fibrin over
a range of relevant RBC counts. The present study was
restricted to clots formed from purified fibrinogen and
washed RBCs. Because of the known compartmentalization
of fibrin and cellular components within thrombi,10,22 2
extreme model states were evaluated (Figure 1). At increasing
RBC occupancy, identical amounts of fibrin were present
either in clots with constant total volume (and consequently
increasing extracellular fibrin concentration; Model 1) or in
clots with volume expanding proportionally to the increase of
RBC content (preserving constant extracellular fibrin concen-
tration; Model 2). In all cases, the intercellular fibrin was
composed of thinner fibers and smaller pores, resulting in a
denser network compared with the cell-free fibrin, as illus-
trated for Model 1 in Figure 2 (Supplemental Figure II).
The role of the integrin-dependent RBC-fibrinogen inter-
action in the modification of fibrin structure was approached
with the addition of the integrin blocker eptifibatide (Figure
2A) at a concentration that has been shown to be efficient in
the inhibition of fibrinogen binding to RBCs.8 Because the
most striking changes in the fibrin structure related to the
presence of RBCs and eptifibatide appeared to be in the fiber
diameter, this parameter was quantitatively evaluated using
the morphometric approach illustrated in Figure 2B. In all
cases, the increase in the clot occupancy by RBCs was
coupled to a decrease in the fiber diameter (Table). This
effect was more pronounced in Model 1 (at increasing
extracellular fibrinogen concentrations), where 40% (v/v)
RBC occupancy resulted in a more than 2-fold diameter
Figure 1. Schemes of the experimental setups used in the eval-
uation of fibrinolysis in the presence of red blood cells (RBCs).
The total volume (Vt) of the clot was partially occupied by RBCs,
whereas fibrinogen (converted to fibrin) occupied the extracellu-
lar volume (Vec) at concentration [Fg]ec. In both models, the total
amount of fibrin (Vec  [Fg]ec) was identical at any RBC occu-
pancy, which was maintained by the indicated increase in [Fg]ec
at decreasing Vec in Model 1 or at constant [Fg]ec and Vec in
Model 2. Because in Model 1 two variables (fibrinogen concen-
tration and RBC occupancy) were changed in parallel, separate
cell-free clots were also prepared at identical fibrinogen concen-
trations and used as a reference for each RBC occupancy to
isolate the RBC effects in the experiments performed according
to this model.
Figure 2. Changes in the fibrin network structure caused by red blood cells (RBCs) and eptifibatide. The scanning electron microscope
images in A illustrate the fibrin structure in clots of identical volume and fibrinogen content in the absence or presence of 20% RBCs
(note that expulsion of fibrinogen by RBCs increases the extracellular fibrinogen concentration in this model). B, Fiber diameter mea-
sured from the scanning electron microscope images for a range of RBC occupancy in the same clot model. Probability density func-
tions (PDF) of the empirical distribution (black histogram) and the fitted lognormal theoretical distribution (gray curves) are presented
with indication of the median and the interquartile range (in parentheses) of the fitted theoretical distributions. In the presence of RBCs,
the parameters of the fitted distributions of the eptifibatide-free and eptifibatide-treated fibers differ at the P0.001 level (for the RBC-
free fibrins, the eptifibatide-related difference is not significant, P0.05). Four replicate samples of each clot type were evaluated in a
single global statistical procedure.
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reduction. On the basis of these results, we propose that in
Model 1 the fiber diameter reflects the outcome of 2 opposing
effects: the fiber-thickening effects of increasing fibrinogen
concentrations in the absence of RBCs (reference values in
column 2 of the Table) and the fiber-thinning effect of
increasing RBC occupancy at constant fibrinogen concentra-
tion (Model 2, Table). Although it had no effect on the
architecture of clots formed from purified fibrinogen, eptifi-
batide at 20 mol/L completely reversed the changes in fiber
diameter caused by RBCs in Model 2, supporting the role of
the specific RBC receptor-fibrinogen interaction in the as-
sembly of the final fibrin structure. In Model 1, the influence
of eptifibatide was less pronounced, resulting in up to 40%
reduction in the fiber-thinning effect of RBCs, probably
related to the stronger competition on behalf of the increasing
fibrinogen concentration in this experimental setup.
When fibrinogen containing plasminogen is mixed with
thrombin and tPA, following clotting the plasminogen acti-
vator is uniformly dispersed in the total volume of the clot
and the generated plasmin dissolves the fibrin matrix. As a
result of proteolysis, fibrin loses its mechanical stability, and
thus a steel ball placed on the top of the clot will descend in
response to gravity. This global lytic assay system is inti-
mately related to the biological function of fibrin, because it
reflects the changes in the mechanical stability of the fibrin
matrix. The time to achieve complete collapse of the clot can
be used as a global end-point indicator of this assay. If
identical quantities of fibrin are degraded, this lysis time
depends on the combined effect of several factors (stability of
the initial fibrin network, rate of plasminogen activation,
catalytic efficiency of plasmin in various fibrin structures).
Although the constant amount of fibrin was maintained
differently in our Models 1 and 2 defined above, in both
situations the presence of 10% and 40% (v/v) RBCs slowed
down the fibrinolysis induced by incorporated tPA, and
eptifibatide partially or completely reversed the RBC effect
(Figure 3). In view of our recent data on the differential
impact of fibrin structure on plasminogen activation and
fibrin dissolution,19 the discordant response of the 20% (v/v)
RBC-fibrin clots in this complex fibrinolytic assay indicated
the necessity to dissect the role of RBCs in these 2 stages of
the process.
When tPA was applied to the surface of fibrin containing
plasminogen and increasing numbers of RBCs, plasmin was
generated on a fibrin surface with decreasing area (part of the
interface was occupied by RBCs) and varying structure
(Figure 2 and the Table), which is also known to affect
plasminogen activation.19 Under the conditions of Model 1,
after a 30-minute activation on the surface of fibrin contain-
ing 10% to 20% (v/v) RBCs, the plasmin level peaked at
36.6% to 44.6% over the cell-free control values, but further
increase in the RBC content moderated this stimulation to
25.6% at 40% (v/v) RBCs (Figure 4A). It is noteworthy that
on the surface of cell-free fibrin formed from fibrinogen at
concentrations equivalent to the extracellular values in Model
1, plasmin generation decreased with increasing fibrinogen
concentrations (22.2% less plasmin formed at 12.4 mol/L
fibrinogen than at 7.4 mol/L; data not shown). In contrast to
the bell-shaped dependence of plasminogen activation on the
RBC count in Model 1, a linear decrease in the amount of
plasmin generated could be observed at increasing RBC
occupancy and constant extracellular fibrinogen concentra-
tion (Figure 4B). Because the RBC-occupied area of the
activation interface was the same in both models for identical
volume occupancy, the differences in plasmin generation can
be attributed to the variations in fibrin structure. In line with
this, eptifibatide at 20 mol/L moderated the effect of the
highest RBC counts in both models of fibrin-dependent
plasminogen activation (in the absence of fibrin, eptifibatide
modestly stimulated the tPA-induced plasminogen activation,
resulting in 20% more plasmin at 30 minutes; data not
shown).
The interplay of tPA, fibrin, and RBCs at the fluid phase–clot
interface was approached with confocal microscopic observation
of tPA-GFP penetration in the clot, propagation of the lytic
front of orange fluorescent–labeled fibrin, and release of
fluorescent-labeled RBCs from the clot. In agreement of our
and others’ earlier findings,19,23 within 10 minutes after
Table. Fiber Diameter (nm) of Fibrin Clots With Varying Red Blood Cell Content
Volume Occupancy






RBCRBC Reference RBC Reference
10% 110† (29) 170† (91) 160† (90) 140† (70) 170† (86) 170 (83)
20% 90* (26) 170 (99) 100* (50) 160* (95) 180 (86) 180* (88)
40% 96* (31) 200* (100) 92* (33) 140* (87) 210* (110) 170 (86)
Fibrin was prepared and the scanning electron microscope (SEM) images were analyzed as illustrated in Figure 2.
The median and interquartile range (in parentheses) of the diameter distributions are presented in nm units (4
replicate samples of each clot type were evaluated in a single statistical procedure). Reference values refer to cell-free
fibrin prepared from fibrinogen at concentrations equivalent to the extracellular concentrations resulting from the
expulsion of fibrinogen by the respective red blood cell (RBC) occupancy as described for Model 1 in Methods (8.2,
9.2, and 12.4 mol/L in increasing order of RBC occupancy). For Model 2, the extracellular concentration of fibrinogen
was always 7.4 mol/L, and thus a single reference value of 150 (71) nm was used in the absence of eptifibatide
and 160 (83) nm in the presence of 20 mol/L eptifibatide. All differences between fiber diameters in the presence
of RBCs and the respective reference values in Model 1 are significant at the P0.001 level.
*,†Additional significant (P0.001) differences are also indicated between two subsequent values along the
columns from top to bottom (*) or in comparison with the cell-free 7.4 mol/L fibrin (†).
Wohner et al Lysis of RBC-Fibrin Clots 2309
 by guest on September 14, 2011http://atvb.ahajournals.org/Downloaded from 
application of tPA-GFP to the surface of preformed fibrin, a
sharp zone of intense tPA-related fluorescence was formed on
the surface of cell-free fibrin (Figure 5A) and preserved
throughout the lysis observation period (Figure 5B). In
contrast, the presence of RBCs prevented this accumulation
of tPA (Figure 5A and 5B). The progress of fibrin dissolution
could be monitored on the basis of the position of the
boundary layer of the fluorescent fibrin phase (Figure 5C).
The presence of RBCs at 20% to 40% in the clot significantly
slowed down the dissolution of fibrin after a 25-minute
exposure to tPA, with the greatest difference at 30 minutes
(3.5-fold shorter distance run by the lytic front), followed by
a catch-up phase, but the difference remaining almost 2-fold
at 55 minutes. Eptifibatide did not affect the progress of lysis
in the absence of RBCs, but it moderated the inhibiting effect
of RBCs. The release of RBCs from the clot occurred in
parallel with the progress of the lytic process, as evidenced by
the lack of RBCs in the fluid phase in the early stage of
dissolution (Figure 5A) and their abundance out of the clot at
later stages (Figure 5B).
Discussion
The hemostatic function of whole blood is a delicate balance
of coagulation and fibrinolytic pathways, which is profoundly
Figure 3. Fibrinolysis induced by clot-incorporated tissue plas-
minogen activator (tPA) in the presence of red blood cells. Clots
of various red blood cell (RBC) occupancy contained 5 mg of
fibrin at constant volume and increasing extracellular concentra-
tions (A) or 2 mg of fibrin at increasing volumes and constant
extracellular concentration (B), as well as plasminogen and tPA
at identical extracellular concentrations as detailed in Methods.
After 15 seconds of clotting, a steel ball was placed on the sur-
face of the clots, and the lysis time was measured in the
absence (black columns) or presence (gray columns) of eptifi-
batide. Data are presented as mean and SD (n4). *Significant
(P0.05) difference between the fibrin without RBCs. Signifi-
cant (P0.05) difference between eptifibatide-free and
eptifibatide-treated fibrins with identical RBC content.
Figure 4. Plasminogen activation on the surface of fibrin con-
taining red blood cells (RBCs). Plasmin activity (A405/min) was
measured after 30 minutes of activation by tissue plasminogen
activator (tPA) applied to the surface of clots with embedded
plasminogen as described in Methods. The same RBC-fibrin
model clots were used as in Figure 3 (A, varying extracellular
fibrinogen concentration; B, constant fibrinogen concentration).
In A, only the cell-free control for 9.2 mol/L fibrin concentra-
tion, corresponding to 20% RBC clot occupancy, is shown,
whereas in B, the control refers to 7.4 mol/L fibrin. Data are
presented as mean and SD (n4) in the absence (black col-
umns) or presence (gray columns) of 20 mol/L eptifibatide.
*Significant (P0.05) difference between the fibrin without
RBCs. Significant (P0.05) difference between eptifibatide-free
and eptifibatide-treated fibrins with identical RBC content.
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affected by RBCs. Although severely anemic patients show a
bleeding trend, which can be reversed with transfusion of
washed RBCs,2 the increased RBC mass of polycythemia
vera patients is coupled to frequent (in more than one third of
the patients) thrombotic complications.24 However, the local
number of RBCs in thrombi does not necessarily correlate
with the systemic RBC count, because some complicating
factors, such as flow conditions and variable geometry,
especially at stenotic sites, will influence the distribution of
the cellular elements in the lumen of blood vessels.25 Thus,
not surprisingly, variable amounts of RBCs can be detected in
thrombi removed surgically from large arteries (Supplemen-
tal Figure I). The major goal of the present study was to
evaluate the contribution of RBCs to clot stability from the
aspect of fibrinolysis. Because in a plasma environment
RBCs could affect the final clot structure through interactions
at multiple steps of the coagulation process (eg, exposing
negatively charged phospholipids that provide surface for the
assembly of coagulation factor complexes)26 and to avoid the
interference of plasma inhibitors, we evaluated clots prepared
from purified fibrinogen and washed RBCs. Thus, initiating
dissolution with plasminogen and tPA at precisely known
concentrations a relatively limited number of variables
needed to be considered in the evaluation of the fibrinolytic
side of the hemostatic balance. The study of clot dissolution
was approached in 2 experimental setups. In the model with
incorporated tPA, the activator was uniformly dispersed
within the RBC-fibrin clots at a concentration of 1 nmol/L,
which is relevant to the amount of tPA measured in human
arterial thrombi,27 thus mimicking the situation in hemostatic
plugs at sites of vascular injury when coagulation and fibrino-
lysis are initiated simultaneously. In the second setup, tPA was
applied to the surface of preformed RBC-fibrin clots at a
concentration of 60 nmol/L, relevant to the values maintained in
blood in the course of enzymatic thrombolysis,28 thus mimicking
the therapeutic systemic administration of plasminogen activa-
tors. Despite the differences in the experimental approaches, in
both settings the effect of RBCs was consistent; increasing RBC
occupancy of the clot resulted in resistance to lysis (Figures 3
and 5C). This antifibrinolytic effect of RBCs, which is expressed
at physiologically relevant RBC counts, shifts the balance of
coagulation/fibrinolysis in favor of clotting and may prevent the
premature dissolution of hemostatic plugs or contribute to
the thrombotic complications in polycythemia vera. In addition,
the heterogeneous RBC composition of thrombi (Supplemental
Figure I) may be one of the factors contributing to the variability
in the lytic susceptibility during thrombolytic therapy of myo-
cardial infarction and stroke.
The mechanism of RBC-related fibrinolytic resistance was
approached using ultrastructural and kinetic methods. Scan-
ning electron microscope imaging of the fibrin structures
formed in the presence of RBCs evidenced thinner fibers in
the RBC-rich areas (Figure 2). These measurements were
performed in 2 extreme settings: either keeping the total
amount of fibrin constant, with a consequent increase in the
extracellular fibrinogen concentration in parallel with the
RBC-excluded volume, or at a constant extracellular fibrin-
ogen concentration for any RBC occupancy (Figure 1). In the
second setting, a dose-dependent decrease in fiber diameter
was observed with increasing RBC occupancy of the clot
(Table), whereas in the first setting this effect was counter-
acted by the thickening effect of rising fibrinogen concentra-
tion (Table, reference values), with the outcome seen in
Figure 2B and the Table (Model 1, RBC values). The lysis
time measured in the ball sedimentation assay (Figure 3) was
inversely correlated with the established changes in fiber
diameter and not directly with the RBC occupancy of the
clots. When eptifibatide, a blocker of the RBC fibrinogen
receptor, reversed the RBC effect on the fiber structure
(Figure 2 and the Table), it also reversed the RBC-related
inhibition of fibrinolysis (Figures 3 and 5C). Thus, RBC-
induced modification of fibrin structure appears to be a major
Figure 5. Effect of red blood cells on fibrinolysis induced by tis-
sue plasminogen activator (tPA) applied to the surface of clots.
Fibrin clots were prepared from fibrinogen containing Alexa
Fluor 546–labeled fibrinogen, Vybrant DiD–labeled red blood
cells (RBCs), and plasminogen. Following clotting, tPA-green
fluorescent protein (GFP) was added to fibrin, and the fluid-fibrin
interface was monitored by confocal laser scanning microscopy
using triple fluorescent tracing at the indicated wavelengths. The
images were taken 5 (A) and 40 (B) minutes after the addition of
tPA-GFP (the tPA signal is shown in green, the fibrin in red, and
the RBCs in white). C, Distance run by the fibrin boundary layer
in the course of lysis (mean and SD of 3 measurements). The
numbers next to the curves in the same color indicate the vol-
ume occupancy by RBCs. In some experiments, fibrin contained
20 mol/L eptifibatide (dashed lines).
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mechanism in the lytic resistance of clots with RBC content.
These results are in agreement with earlier findings that if the
fiber diameter is reduced by different factors, the overall rate
of fibrin dissolution is slower in similar lytic models with
clot-incorporated19,29 or surface-applied30 activators.
Because the lytic assays discussed above reflect a global
measure of the combined outcome of the 2 stages of fibrino-
lysis (plasminogen activation and proteolysis of fibrin),
separate kinetic and confocal microscopic measurements
were performed in attempt to identify discrete effects of
RBCs. The plasmin generated in the course of plasminogen
activation on the surface of clots in Model 1 increased in the
presence of RBCs in the clot (Figure 4A), which is surprising
in view of the RBC-related suppression of fibrin dissolution.
Furthermore, plasminogen activation on the surface of clots
in Model 2 shows a dose-dependent decreasing trend at rising
RBC occupancy (Figure 4B). These discordant findings can
be explained by the simultaneous action of 2 opposing
factors. First, greater RBC occupancy of clots results in
thinner fibers (Table), which are a better template for tPA-
catalyzed plasminogen activation.19 Second, the presence of
more RBCs in the clot volume results in more cells on the clot
surface and a consequent relative increase in the area devoid
of plasminogen and inert in terms of plasmin generation. The
reduction in interface area occupied by plasminogen-pres-
enting fibrin translates into less plasmin generation. In the
setting of the Figure 4A assay, the thinner fiber network gains
higher density at increasing fibrinogen concentrations, and
thus, the effect of template quality coupled to higher cofactor
concentration dominates. In the setting of a constant fibrino-
gen concentration (Figure 4B), increasing the surface taken
by RBCs limits plasminogen activation despite the thinner
fibers. Independently of the variations in plasmin generation,
in both setups RBCs slow down fibrin dissolution (Figure 3),
which suggests that the plasmin-catalyzed proteolytic stage
prevails in the control of fibrinolysis at increasing RBC
occupancy. The confocal images of fibrin exposed to tPA-
GFP (Figure 5A and 5B) provide direct evidence for the
limited access of tPA to activatable substrate; the accumula-
tion of tPA in the interfacial fibrin layer is definitely retarded
in the presence of RBCs.
This interpretation of the observed changes in plasminogen
activation on the surface of RBC-fibrin clots is further
supported by the effects of eptifibatide in these assays (Figure
4). This blocker of the RBC fibrinogen receptor increases the
fiber diameter (Table) and thus eliminates RBC-related
changes in the structure of the fibrin template that favor
plasminogen activation,19 leaving unopposed the effect of the
expanding RBC-occupied surface with a consequent decline
in plasminogen activation. In the absence of fibrin, eptifi-
batide stimulates plasminogen activation (data not shown),
and this effect persists if activation occurs on the surface of
cell-free fibrin with less efficient template function (thicker
fibers at 8.2 mol/L or higher fibrinogen concentration,
Figure 4A), but not on the thinner fibers with better cofactor
function in the tPA-catalyzed plasminogen activation (Figure
4B). The reported observations for the generation of plasmin
in the presence of RBCs indicate that binding of the receptor
blocker to RBCs eliminates its direct effect on plasminogen
activation and likewise moderates the RBC effects. The data
on the effects of eptifibatide in plasminogen activation
(Figure 4) and fibrinolytic (Figure 3) assays suggest that the
RBC fibrinogen receptor mediates, at least in part, the
RBC-related lytic resistance of fibrin.
In summary, our present report unravels a clot-stabilizing
function for RBCs based on suppressed tPA-induced fibrino-
lysis in RBC-modified fibrin structures. In addition to steric
hindrance, RBCs modulate fibrinolysis through a specific
fibrinogen receptor, as evidenced by the effects of eptifi-
batide, a cyclic heptapeptide that reversibly inhibits the
binding of fibrinogen to IIb3 integrin. This IIb3 antago-
nist is used in clinical practice as an antiplatelet agent,31 but
its newly described role in RBC-containing clots extends our
understanding of its favorable antithrombotic action by over-
coming the resistance to lysis of RBC-rich thrombi.
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